Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | IDH1 mutant |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05283109 | Phase I | P30-EPS + Poly ICLC | ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM (ETAPA I) | Active, not recruiting | USA | 0 |
| NCT03139916 | Phase II | Bavituximab + Temozolomide | Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma | Completed | USA | 0 |
| NCT05188508 | Phase II | Olaparib + Pembrolizumab + Temozolomide | Pembrolizumab, Olaparib, and Temozolomide for People with Glioma | Recruiting | USA | 0 |
| NCT03701295 | Phase Ib/II | Azacitidine + Pinometostat | Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement | Completed | USA | 0 |
| NCT04396860 | Phase II | Temozolomide Ipilimumab + Nivolumab | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | Active, not recruiting | USA | 0 |
| NCT06831526 | Phase I | Azeliragon + Temozolomide | Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma | Recruiting | USA | 0 |
| NCT04945148 | Phase II | Metformin + Temozolomide | Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide (OPTIMUM) | Recruiting | ITA | FRA | 0 |
| NCT03749187 | Phase I | Pamiparib + Temozolomide | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017) | Recruiting | USA | 0 |
| NCT06413706 | Phase II | Abemaciclib + Temozolomide Temozolomide | A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Recruiting | USA | ROU | NLD | ITA | FRA | ESP | DNK | BEL | AUS | 1 |
| NCT04908176 | Phase I | Avapritinib + Midazolam | A Drug-drug Interaction Study of Avapritinib and Midazolam | Completed | USA | 0 |
| NCT02073994 | Phase I | Ivosidenib | Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | Completed | USA | FRA | 0 |
| NCT03430791 | Phase II | Ipilimumab + Nivolumab Nivolumab | Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma | Terminated | USA | 0 |
| NCT05401097 | Phase II | Azacitidine + Enasidenib + Venetoclax Azacitidine + Ivosidenib + Venetoclax | IDH Targeted/non- Targeted Vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) | Recruiting | USA | 0 |
| NCT04729959 | Phase II | Atezolizumab + Tocilizumab | Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
| NCT04955938 | Phase I | Enasidenib + Fedratinib Fedratinib + Ivosidenib | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | Withdrawn | USA | 0 |
| NCT05376800 | Phase I | BI 907828 | A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma | Completed | USA | ESP | BEL | 0 |
| NCT07223034 | Phase I | lutetium Lu 177 vipivotide tetraxetan + Temozolomide | A Study of 177Lu-PSMA-617 in People With Gliomas | Recruiting | USA | 0 |
| NCT06636162 | Phase I | DSP-0390 | Window of Opportunity Study of DSP-0390 in Gliomas | Recruiting | USA | 0 |
| NCT06566742 | Phase II | Olutasidenib | A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. | Recruiting | USA | 0 |
| NCT07260175 | Phase II | Ivosidenib | Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma (adIVO) | Recruiting | DEU | 0 |
| NCT04606316 | Phase I | Nivolumab Ipilimumab + Nivolumab | Surgical Nivolumab And Ipilimumab For Recurrent GBM | Active, not recruiting | USA | 0 |
| NCT04762602 | Phase I | HMPL-306 | A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations | Terminated | USA | ESP | 0 |
| NCT05218408 | Phase Ib/II | Cyclophosphamide + Fludarabine CYNK-001 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (CYNK001GBM02) | Withdrawn | 0 | |
| NCT05180825 | Phase II | Vinblastine Trametinib | Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy (PLGG - MEKTRIC) | Recruiting | FRA | 0 |
| NCT02858895 | Phase II | MDNA55 | Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma | Completed | USA | 0 |
| NCT07032727 | Phase II | Olutasidenib + Ruxolitinib Gilteritinib + Olutasidenib + Venetoclax Gilteritinib + Olutasidenib Cladribine + Cytarabine + Olutasidenib + Venetoclax Cladribine + Cytarabine + Olutasidenib | Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations | Recruiting | USA | 0 |
| NCT07130695 | Phase I | Olutasidenib | Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation | Not yet recruiting | USA | 0 |
| NCT07036380 | Phase II | Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine + MP0317 | MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (TACTIC) | Not yet recruiting | FRA | 0 |
| NCT04774393 | Phase Ib/II | Decitabine and Cedazuridine + Ivosidenib + Venetoclax Decitabine and Cedazuridine + Enasidenib + Venetoclax | Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
| NCT06455605 | Phase Ib/II | 2141 V-11 + D2C7-IT | D2C7-IT + 2141-V11 Combination Post-resection in rGBM | Recruiting | USA | 0 |
| NCT06776250 | Phase II | Tarlatamab | Study of How Safe and Effective Tarlatamab is in Brain Cancers | Recruiting | CAN | 0 |
| NCT05627323 | Phase I | CHM-1101 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | Active, not recruiting | USA | 0 |
| NCT06661915 | Phase II | Decitabine and Cedazuridine Decitabine and Cedazuridine + ORY-1001 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | Recruiting | USA | 0 |
| NCT03207347 | Phase II | Niraparib | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | Completed | USA | 0 |
| NCT03991832 | Phase II | Durvalumab + Olaparib | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors (SOLID) | Recruiting | CAN | 0 |
| NCT07089641 | Phase I | ERAS-801 | ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial (ERAS801-SARG) | Recruiting | USA | 0 |
| NCT06478212 | Phase Ib/II | Temozolomide + Vorasidenib | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma | Recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | AUT | 2 |
| NCT04015700 | Phase I | GNOS-PV01 + Rocakinogene sifuplasmid | Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma | Active, not recruiting | USA | 0 |
| NCT07243470 | Phase Ib/II | Tarlatamab + Temozolomide | Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors (TARLATEM) | Recruiting | FRA | 0 |
| NCT07177079 | Phase I | Decitabine + Venetoclax Azacitidine + Venetoclax Azacitidine + Venetoclax + Vitamin C Decitabine + Venetoclax + Vitamin C | High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) | Not yet recruiting | USA | 0 |
| NCT05879120 | Phase II | Pembrolizumab | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma | Withdrawn | USA | 0 |
| NCT03158389 | Phase Ib/II | Vismodegib Alectinib Idasanutlin Temsirolimus Atezolizumab Palbociclib APG101 | NCT Neuro Master Match - N²M² (NOA-20) (N²M²) | Completed | DEU | 0 |
| NCT06934889 | Phase I | ABBV-637 + ERAS-801 ABBV-637 + Temozolomide ERAS-801 + Mirzotamab clezutoclax Mirzotamab clezutoclax + Temozolomide | Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma | Recruiting | USA | 0 |
| NCT05417594 | Phase Ib/II | AZD9574 + Trastuzumab deruxtecan AZD9574 + Datopotamab deruxtecan AZD9574 AZD9574 + Temozolomide | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) | Recruiting | USA | SWE | GBR | ESP | DEU | AUS | 1 |
| NCT05766514 | Phase II | Cladribine + Cytarabine + Decitabine Decitabine + Venetoclax Azacitidine + Venetoclax | Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction | Withdrawn | USA | 0 |
| NCT06668584 | Phase Ib/II | Olutasidenib | A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients with IDH1-mutated Myeloid Malignancies | Recruiting | USA | 0 |
| NCT05474378 | Phase I | Retroviral vector transduced B7-H3 CAR T cells | B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme | Recruiting | USA | 0 |
| NCT06297512 | Phase II | Doxorubicin + Temozolomide | Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). | Recruiting | ITA | 0 |
| NCT02525692 | Phase II | Dordaviprone | Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma | Terminated | USA | 0 |
| NCT02981940 | Phase II | Abemaciclib | A Study of Abemaciclib in Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
| NCT06991101 | Phase II | Ruxolitinib + Temozolomide Temozolomide | Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma | Not yet recruiting | USA | 0 |
| NCT05432375 | Phase I | Tinostamustine | Study of Tinostamustine for Adjuvant Treatment of Glioblastoma | Completed | ESP | CHE | 0 |
| NCT03503409 | Phase II | Ivosidenib | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | Active, not recruiting | ITA | FRA | 0 |
| NCT06809322 | Phase III | Vorasidenib | Vorasidenib Maintenance for IDH Mutant Astrocytoma (VIGOR) | Not yet recruiting | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CHE | BEL | AUT | 0 |
| NCT03718767 | Phase II | Nivolumab | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | Active, not recruiting | USA | 0 |
| NCT07110246 | Phase II | Dabrafenib + Trametinib | Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas (PNOC037) | Recruiting | USA | 0 |
| NCT05463848 | Phase II | Olaparib + Pembrolizumab + Temozolomide Pembrolizumab | Surgical Pembro +/- Olaparib W TMZ for RGBM | Recruiting | USA | 0 |
| NCT04195555 | Phase II | Ivosidenib | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | AUS | 1 |
| NCT02481154 | Phase I | Vorasidenib | Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation | Completed | USA | 0 |
| NCT04278781 | Phase II | Ivosidenib | AG-120 in People With IDH1 Mutant Chondrosarcoma | Active, not recruiting | USA | 0 |
| NCT05432804 | Phase Ib/II | Selinexor + Temozolomide Temozolomide | Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | Suspended | USA | 0 |
| NCT03970447 | Phase II | VAL-083 ADI-PEG 20 AZD1390 VT1021 Lomustine Regorafenib Temozolomide GDC-0084 | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE) | Recruiting | USA | FRA | DEU | CHE | CAN | AUS | 0 |
| NCT03878095 | Phase II | Ceralasertib + Olaparib | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | Active, not recruiting | USA | 0 |
| NCT02428855 | Phase II | Dasatinib | Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma | Completed | USA | 0 |
| NCT06258018 | Phase Ib/II | Niraparib + Temozolomide | Niraparib and Temozolomide in Patients Glioblastoma (ONC-2022-001) | Not yet recruiting | ITA | 0 |
| NCT03220646 | Phase II | Abemaciclib | Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | Active, not recruiting | USA | 0 |
| NCT05406700 | Phase I | Niraparib | Niraparib In Recurrent IDH 1/2 Gliomas | Active, not recruiting | USA | 0 |
| NCT05052957 | Phase II | Carmustine + Filgrastim + O6-benzylguanine + Temozolomide | hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (hSTAR GBM) | Recruiting | USA | 0 |
| NCT02989857 | Phase III | Ivosidenib | Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) | Completed | USA | ITA | GBR | FRA | ESP | 1 |
| NCT06291987 | Phase I | Ivosidenib + Ruxolitinib | Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (MPN) | Recruiting | USA | 0 |
| NCT04559230 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan in Recurrent Glioblastoma | Recruiting | USA | 0 |
| NCT06597734 | Phase II | Decitabine and Cedazuridine + Olutasidenib Azacitidine + Olutasidenib Decitabine + Olutasidenib | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm | Recruiting | USA | 0 |
| NCT05345002 | Phase II | Retifanlimab + Tretinoin | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | Recruiting | USA | 0 |
| NCT02492737 | Phase I | Vorasidenib | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | Completed | USA | FRA | 0 |
| NCT05538572 | Phase I | PRT3645 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | Completed | USA | 1 |
| NCT06543381 | Phase I | Olutasidenib | Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant | Recruiting | USA | 0 |
| NCT02968940 | Phase II | Avelumab | Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma | Completed | USA | 0 |
| NCT05099003 | Phase Ib/II | Selinexor | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Recruiting | USA | NZL | CAN | AUS | 0 |
| NCT02071862 | Phase I | Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | Completed | USA | 0 |
| NCT04764474 | Phase I | HMPL-306 | A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH | Terminated | USA | ESP | 0 |
| NCT05743595 | Phase I | Personalized cancer vaccine + Retifanlimab | Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | Recruiting | USA | 0 |
| NCT06719362 | Phase I | M3T01 M3T01 + Temozolomide M3T01 + Pembrolizumab Fluorouracil + Leucovorin + M3T01 + Oxaliplatin + Pembrolizumab | A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies | Recruiting | USA | 0 |
| NCT04988555 | Phase Ib/II | DSP-5336 | A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutation | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | 4 |
| NCT05465954 | Phase II | NT-I7 + Pembrolizumab | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | Recruiting | USA | 0 |
| NCT05588141 | Phase Ib/II | Zotiraciclib | A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations | Recruiting | USA | 0 |
| NCT03557359 | Phase II | Nivolumab | Nivolumab for Recurrent or Progressive IDH Mutant Gliomas | Completed | USA | 0 |
| NCT05756777 | Phase I | Gilteritinib + Ivosidenib Enasidenib + Gilteritinib | A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |
| NCT05222802 | Phase I | ERAS-801 | A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) | Active, not recruiting | USA | 0 |
| NCT04555577 | Phase I | Peposertib Temozolomide | Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma | Recruiting | USA | 0 |
| NCT05326464 | Phase III | Tofacitinib | Tofacitinib in Recurrent GBM Patients | Active, not recruiting | USA | 0 |
| NCT04629209 | Phase II | Dordaviprone | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | Withdrawn | USA | 0 |
| NCT02576444 | Phase II | Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib | OLAParib COmbinations (OLAPCO) | Terminated | USA | 0 |
| NCT04576117 | Phase III | Selumetinib Selumetinib + Vinblastine | A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma | Active, not recruiting | USA | CAN | 0 |
| NCT07075016 | Phase III | Azacitidine + Ivosidenib + Venetoclax Azacitidine + Ivosidenib | Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy (EVOLVE 1) | Recruiting | SWE | NOR | NLD | LTU | ITA | IRL | GBR | FRA | FIN | EST | ESP | DNK | DEU | CHE | BEL | AUT | 0 |
| NCT04118036 | Phase II | Abemaciclib + Pembrolizumab | Abemaciclib + Pembrolizumab In Glioblastoma | Withdrawn | USA | 0 |
| NCT02632708 | Phase I | Enasidenib + Etoposide + Mitoxantrone Cytarabine + Enasidenib Cytarabine + Idarubicin + Ivosidenib Cytarabine + Daunorubicin + Enasidenib Cytarabine + Enasidenib + Idarubicin Etoposide + Ivosidenib + Mitoxantrone Cytarabine + Ivosidenib Cytarabine + Daunorubicin + Ivosidenib | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | Active, not recruiting | USA | NLD | DEU | 0 |
| NCT03127735 | Phase I | BAY1436032 | BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML) | Completed | USA | DEU | 0 |
| NCT03173248 | Phase III | Azacitidine Azacitidine + Ivosidenib | Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE) | Active, not recruiting | USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUT | AUS | 6 |
| NCT06717958 | Phase II | Ivosidenib | Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation (PIVOT) | Recruiting | DEU | 0 |
| NCT03922555 | Phase I | Decitabine and Cedazuridine | ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas | Recruiting | USA | 0 |
| NCT03047993 | Phase Ib/II | Azacitidine + Telaglenastat | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | Completed | USA | 0 |
| NCT05183204 | Phase II | GDC-0084 + Metformin | Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma | Recruiting | USA | 0 |
| NCT02677922 | Phase Ib/II | Azacitidine + Ivosidenib Azacitidine Azacitidine + Enasidenib | A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy | Active, not recruiting | USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 2 |
| NCT03212274 | Phase II | Olaparib | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | Active, not recruiting | USA | 0 |
| NCT06095375 | Phase I | Regorafenib + Temozolomide | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2) | Active, not recruiting | ITA | 0 |